Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Decision-Making tool aims to prevent bleeding in blood thinner users

NCT ID NCT06401863

Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a computer tool called DDInteract that helps doctors and patients make safer decisions about blood thinners. The tool calculates a person's risk of bleeding and lets them explore 'what if' scenarios. About 3,700 adults on blood thinners will take part across three U.S. clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shared decision making tool (DDInteract)
What this could lead to
If successful, this tool could help doctors and patients make safer choices about blood thinners, reducing the risk of serious bleeding.
What could go wrong
This is an implementation study, not a drug trial. The tool may not change prescribing habits or reduce bleeding rates as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,691 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be at least 21 years of age or older * Receive more than one prescription of an oral anticoagulant (i.e. warfarin, apixaban, edoxaban, dabigatran, rivaroxaban) Exclusion Criteria: * Individuals not able to speak English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticoagulants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gastrointestinal Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticoagulants Drug interactions

Contacts and locations

Locations

  • University of Colorado. School of Medicine

    Denver, Colorado, 80045, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

  • Vanderbilt University

    Nashville, Tennessee, 37235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.